Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 12% of the time (422 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2009-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: depressionreleasesubjectsivcurrent
  Phrases that lowered it: objectivethe efficacyevaluateversuscombination
• Phase: 3 (lowers risk) · Design
• Sponsor's past termination rate: 6.7% (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 288 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Sponsor's past trials: 520 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 11.1% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 65 (raises risk) · Who can join
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: 78.3% (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Number of arms: 3 (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy NCT00857584 · started 2009 · scored riskier than 21% of active trials completed
• Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression NCT01256177 · started 2010 · scored riskier than 27% of active trials completed
• Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression NCT00883493 · started 2009 · scored riskier than 8% of active trials completed
• The Quietude Study: Quetiapine Use for Agitated Depression NCT01363310 · started 2010 · scored riskier than 39% of active trials terminated
• A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder NCT04338321 · started 2020 · scored riskier than 34% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.